Nanostructured lipid carriers-based drug delivery for treating various lung diseases: A State‐of‐the‐Art Review

Patil, Tulshidas S.; Deshpande, Ashwini

doi:10.1016/j.ijpharm.2018.05.070

Cited by 55 publications

(26 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To overcome obstacles in delivering drugs to the pulmonary system, the focus has been shifted toward nanocarrier‐based drug delivery systems, which are being studied and developed to produce effective methods of drug delivery (Patil & Deshpande, ). These nanoparticle‐based drugs can be administered through various routes of drug administration.…”

Section: Nanocarrier‐based Drug Delivery Systemsmentioning

confidence: 99%

“…This field is known as nanomedicine, which is the application of nanotechnology in medicine and pharmacy (Chu et al, ). The advantages of using nanocarrier‐based systems include a large surface area that allows rapid drug absorption, enhanced therapeutic effect due to higher bioavailability, controlled absorption, and distribution with a high degree of specificity and retention, as well as noninvasive nature to improve patient compliance (Patil & Deshpande, ).…”

Section: Nanocarrier‐based Drug Delivery Systemsmentioning

confidence: 99%

“…Different types of NLC are being explored. Examples include general NLC, multifunctional NLC, ligand‐attached NLC, and PEGylated NLC (Patil & Deshpande, ). The therapeutic effects of NLCs on various diseases has been evaluated and studied extensively.…”

Section: Nanocarrier‐based Drug Delivery Systemsmentioning

confidence: 99%

“…Respiratory disease, also known as pulmonary or lung disease, is a general term used to describe any conditions that affect the lungs and other parts of the respiratory system. In this review, the respiratory diseases discussed include asthma, acute lung inflammation, acute lung injury, acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), lung cancer, and lung infection (Chughtai & O'riordan, ; Kim, Paudel, & Kim, ; Patil & Deshpande, ; Wang et al, ; Yhee, Im, & Nho, ).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Targeting neutrophils using novel drug delivery systems in chronic respiratory diseases

Chellappan

Yee

Xuan

et al. 2020

Drug Development Research

View full text Add to dashboard Cite

Neutrophils are essential effector cells of immune system for clearing the extracellular pathogens during inflammation and immune reactions. Neutrophils play a major role in chronic respiratory diseases. In respiratory diseases such as asthma, chronic obstructive pulmonary disease, cystic fibrosis, lung cancer and others, there occurs extreme infiltration and activation of neutrophils followed by a cascade of events like oxidative stress and dysregulated cellular proteins that eventually result in apoptosis and tissue damage. Dysregulation of neutrophil effector functions including delayed neutropil apoptosis, increased neutrophil extracellular traps in the pathogenesis of asthma, and chronic obstructive pulmonary disease enable neutrophils as a potential therapeutic target. Accounting to their role in pathogenesis, neutrophils present as an excellent therapeutic target for the treatment of chronic respiratory diseases. This review highlights the current status and the emerging trends in novel drug delivery systems such as nanoparticles, liposomes, microspheres, and other newer nanosystems that can target neutrophils and their molecular pathways, in the airways against infections, inflammation, and cancer. These drug delivery systems are promising in providing sustained drug delivery, reduced therapeutic dose, improved patient compliance, and reduced drug toxicity. In addition, the review also discusses emerging strategies and the future perspectives in neutrophil-based therapy. K E Y W O R D S nanoparticle, neutrophils, novel drug delivery, pulmonary, respiratory diseases

show abstract

Section: Nanocarrier‐based Drug Delivery Systemsmentioning

confidence: 99%

Section: Nanocarrier‐based Drug Delivery Systemsmentioning

confidence: 99%

Section: Nanocarrier‐based Drug Delivery Systemsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Targeting neutrophils using novel drug delivery systems in chronic respiratory diseases

Chellappan

Yee

Xuan

et al. 2020

Drug Development Research

View full text Add to dashboard Cite

show abstract

“…Additionally, most of the lipophilic drugs are highly soluble in a liquid lipid when compared with a solid lipid. Thus, NLC is an updated version for solid lipid nanoparticles (SLN), where both solid and liquid lipids were present in the oil phase are increasingly preferred over SLN, as it overcomes major disadvantages of SLN, such as low drug loading and drug expulsion related issues [9][10][11].…”

Section: Introductionmentioning

confidence: 99%

Ziprasidone Hydrochloride Loaded Nanostructured Lipid Carriers (Nlcs) for Intranasal Delivery: Optimization and in Vivo Studies

et al. 2019

View full text Add to dashboard Cite

Objective: The present study was an attempt to systemically deliver the most desirable schizophrenia drug, ziprasidone hydrochloride (ZRS) via the intranasal route using nanostructured lipid carrier (NLC) approach. Methods:The desired ZRS loaded NLCs were developed using central composite statistical design and the developed formulation was monitored for improving ZRS bioavailability and their brain targeting efficacy.Results: Pharmacokinetic studies revealed a 10 fold increase (ZRS blood-brain ratio) for NLCs administered through nasal route (in comparison to intravenous route). Similarly, the concentration of ZRS (in the brain) delivered via nasal route exhibits 4 fold increment at all-time points.Conclusion: Therefore, the obtained results suggest a potential nose to brain transport of loaded ZRS by effective bypassing of the Blood-Brain Barrier (BBB). I In nt te er rn na at ti io on na al l J Jo ou ur rn na al l o of f A Ap pp pl li ie ed d P Ph ha ar rm ma ac ce eu ut ti ic cs s

show abstract

Effective Hydrogel Vascular Patch Dual‐Loaded with Cycloastragenol Nanostructured Lipid Carriers and Doxycycline for Repairing Extravascular Injury in Abdominal Aortic Aneurysm

Chen,

Song,

Liu

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

Endovascular aneurysm repair (EVAR) plays a crucial role in the treatment of abdominal aortic aneurysm (AAA) in the clinic, but the aneurysm remains in the patient's body after surgery, continuing to pose a risk of progression. Cycloastragenol (CAG) is proven to be an effective anti‐AAA drug, and its vascular protective effects can be further improved when the hydrophobic CAG is encapsulated into nano‐sized formulations to enhance its bioavailability. In this context, this study developed an extravascular patch hydrogel loaded with CAG nanostructured lipid carriers and a hydrophilic drug of doxycycline hydrochloride (DOX). The extravascular patch delivered onto the mouse abdominal aortas can promote local permeation of hydrophilic/hydrophobic drugs at the vessel sites and provide effective vascular protection against AAA injury induced by elastase. This study introduces a novel and promising approach for AAA treatment, which can serve as a supplementary strategy after EVAR surgery.

show abstract

Nanostructured lipid carriers-based drug delivery for treating various lung diseases: A State‐of‐the‐Art Review

Cited by 55 publications

References 91 publications

Targeting neutrophils using novel drug delivery systems in chronic respiratory diseases

Targeting neutrophils using novel drug delivery systems in chronic respiratory diseases

Ziprasidone Hydrochloride Loaded Nanostructured Lipid Carriers (Nlcs) for Intranasal Delivery: Optimization and in Vivo Studies

Effective Hydrogel Vascular Patch Dual‐Loaded with Cycloastragenol Nanostructured Lipid Carriers and Doxycycline for Repairing Extravascular Injury in Abdominal Aortic Aneurysm

Contact Info

Product

Resources

About